vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and Insight Molecular Diagnostics Inc. (IMDX). Click either name above to swap in a different company.
Insight Molecular Diagnostics Inc. is the larger business by last-quarter revenue ($1.1M vs $1.0M, roughly 1.1× AVAX ONE TECHNOLOGY LTD.). AVAX ONE TECHNOLOGY LTD. runs the higher net margin — -1633.6% vs -2015.4%, a 381.8% gap on every dollar of revenue.
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
AVX vs IMDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.1M |
| Net Profit | $-16.6M | $-23.0M |
| Gross Margin | — | 42.5% |
| Operating Margin | -1522.1% | -2057.5% |
| Net Margin | -1633.6% | -2015.4% |
| Revenue YoY | — | -23.4% |
| Net Profit YoY | -480.2% | 31.5% |
| EPS (diluted) | $32.17 | $-0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $1.1M | ||
| Q3 25 | $525.9K | $260.0K | ||
| Q2 25 | $452.0K | $518.0K | ||
| Q1 25 | $344.4K | $2.1M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | $0 | $115.0K | ||
| Q2 24 | $41.3K | $104.0K | ||
| Q1 24 | — | $176.0K |
| Q4 25 | $-16.6M | $-23.0M | ||
| Q3 25 | $-8.4M | $-10.9M | ||
| Q2 25 | $-8.1M | $-9.7M | ||
| Q1 25 | $-145.5K | $-6.7M | ||
| Q4 24 | — | $-33.5M | ||
| Q3 24 | $-5.8M | $-13.5M | ||
| Q2 24 | $-4.2M | $-4.5M | ||
| Q1 24 | — | $-9.1M |
| Q4 25 | — | 42.5% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 67.6% | ||
| Q1 25 | 22.9% | 62.0% | ||
| Q4 24 | — | 40.0% | ||
| Q3 24 | — | 43.5% | ||
| Q2 24 | 18.4% | 48.1% | ||
| Q1 24 | — | 25.6% |
| Q4 25 | -1522.1% | -2057.5% | ||
| Q3 25 | -496.6% | -4249.2% | ||
| Q2 25 | -328.4% | -1900.0% | ||
| Q1 25 | -600.0% | -318.0% | ||
| Q4 24 | — | -2262.9% | ||
| Q3 24 | — | -11752.2% | ||
| Q2 24 | -2827.7% | -4453.8% | ||
| Q1 24 | — | -5265.3% |
| Q4 25 | -1633.6% | -2015.4% | ||
| Q3 25 | -1588.0% | -4174.6% | ||
| Q2 25 | -1783.4% | -1880.7% | ||
| Q1 25 | -42.2% | -312.0% | ||
| Q4 24 | — | -2255.1% | ||
| Q3 24 | — | -11733.0% | ||
| Q2 24 | -10243.5% | -4355.8% | ||
| Q1 24 | — | -5186.9% |
| Q4 25 | $32.17 | $-0.75 | ||
| Q3 25 | $-5.55 | $-0.34 | ||
| Q2 25 | $-27.60 | $-0.30 | ||
| Q1 25 | $-1.17 | $-0.26 | ||
| Q4 24 | — | $-2.19 | ||
| Q3 24 | $-57.19 | $-0.98 | ||
| Q2 24 | $-83.03 | $-0.36 | ||
| Q1 24 | — | $-1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $-31.5M |
| Total Assets | $195.0M | $25.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $11.6M | ||
| Q3 25 | $894.7K | $18.7M | ||
| Q2 25 | $185.3K | $24.3M | ||
| Q1 25 | $1.4M | $31.0M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $9.3M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $187.0M | $-31.5M | ||
| Q3 25 | $12.2M | $-9.2M | ||
| Q2 25 | $4.1M | $1.1M | ||
| Q1 25 | $6.4M | $10.2M | ||
| Q4 24 | — | $-12.3M | ||
| Q3 24 | $6.7M | $9.7M | ||
| Q2 24 | $11.3M | $22.7M | ||
| Q1 24 | — | $11.6M |
| Q4 25 | $195.0M | $25.8M | ||
| Q3 25 | $16.5M | $43.9M | ||
| Q2 25 | $15.2M | $50.5M | ||
| Q1 25 | $16.8M | $60.4M | ||
| Q4 24 | — | $35.1M | ||
| Q3 24 | $10.8M | $70.2M | ||
| Q2 24 | $15.7M | $74.7M | ||
| Q1 24 | — | $71.0M |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-5.5M |
| Free Cash FlowOCF − Capex | — | $-7.0M |
| FCF MarginFCF / Revenue | — | -616.7% |
| Capex IntensityCapex / Revenue | — | 129.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-5.5M | ||
| Q3 25 | $-2.4M | $-4.5M | ||
| Q2 25 | $-884.1K | $-6.3M | ||
| Q1 25 | $-2.2M | $-5.9M | ||
| Q4 24 | — | $-5.4M | ||
| Q3 24 | $-1.2M | $-5.5M | ||
| Q2 24 | $-919.2K | $-6.0M | ||
| Q1 24 | — | $-3.8M |
| Q4 25 | — | $-7.0M | ||
| Q3 25 | — | $-5.6M | ||
| Q2 25 | — | $-6.6M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-5.6M | ||
| Q2 24 | — | $-6.2M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | -616.7% | ||
| Q3 25 | — | -2135.4% | ||
| Q2 25 | — | -1279.5% | ||
| Q1 25 | — | -288.4% | ||
| Q4 24 | — | -374.5% | ||
| Q3 24 | — | -4884.3% | ||
| Q2 24 | — | -5931.7% | ||
| Q1 24 | — | -2189.8% |
| Q4 25 | — | 129.9% | ||
| Q3 25 | — | 403.8% | ||
| Q2 25 | — | 67.4% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | — | 14.4% | ||
| Q3 24 | — | 75.7% | ||
| Q2 24 | — | 183.7% | ||
| Q1 24 | — | 13.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
